Skip to main content

Table 1 Characteristics of the included studies

From: Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis

Included trialsLocation (s);
Study design
Eligibility criteriaGender (male/female);
mean age (years)
Migraine attacks per monthDrug dosesPrimary efficacy outcomes at 2 hMost frequent TEAEs
ControlTrialControlTrial
Ferrari MD et al., 2010 [16]Multinational; RCTIHS 1.1 & 1.2.14/38; 40.313/75; 38.43.33.52.5–45 mgPain freedom, sustained pain free, other efficacy outcomes such as nausea, photophobia, phonophobia.Dizziness, paresthesia, fatigue, sensation of heaviness, and feeling of relaxation
Färkkilä M et al., 2012 [17]Multinational; RCTIHS 1.1 & 2.111/75; 40.5 ± 10.338/267; 40.2 ± 11.03.1 ± 1.63.3 ± 1.750, 100, 200, 400 mgPain free, headache response, other efficacy outcomes such as nausea, photophobia, phonophobiaDizziness, paresthesia, fatigue, nausea, vertigo and somnolence
Kuca B et al., 2018 [18]USA; RCTIHS 1.1 & 1.2.192/525; 42.4 ± 12.3212/1027; 41.8 ± 11.95.1 ± 1.85.2 ± 2.1100, 200 mgHeadache pain free, MBS free, other efficacy outcomes such as nausea, photophobia, phonophobiaDizziness, paresthesia, fatigue, nausea, lethargy, and palpitations
Goadsby PJ et al., 2019 [19]Multinational; RCTIHS 1.1 & 1.2.1100/545;
42.6 ± 12.9
309/1629; 42.7 ± 12.85.5 ± 2.45.2 ± 2.150, 100, 200 mgHeadac he pain free, MBS free, other efficacy outcomes such as nausea, photophobia, phonophobiaDizziness, paresthesia, fatigue, nausea, lethargy and somnolence
  1. RCT Randomized controlled trial, IHS The International Headache Society criteria
\